創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

創薬シーズ 創薬技術

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
20/03/02 GEM161 Restoration of autophagy and reduction of inflammation Cardiovascular and Metabolic Diseases Oral Oligo-saccharides Phase 2b/3 ready A novel derivative (pat. pend.) of hydroxypropyl-α-cyclodextrin (HPαCD) that down-regulates the PI-system by controlling serum phospholipids and, thereby, reduces endocytosis. βCDs have been shown to be effective in vivo against atherosclerosis (AS), NAFLD, but can cause permanent hearing loss (not applicable to αCDs). Oral αCD is clinically effective against metabolic syndrom, but has low and variable bioavailability. 505(b)(2) is applicable. 問合せ
20/03/02 GEM160 Restoration of autophagy and reduction of inflammation Neuro-degenerative diseases Oral, Intra-thecal Oligo-saccharides Phase 2b/3 ready A novel derivative (pat. pend.) of hydroxypropyl-α-cyclodextrin (HPαCD) that down-regulates serum phospholipids and prevents aging cells from accumulating Aβ/tau (AD), α-syn (PD), myelin (MS), mHTT (HD), SOD1 (ALS), ... . βCDs were effective in vivo against AD and PD, but development was abandoned (except for NPC) due to the risk of permanent hearing loss (not applicable to αCDs). In the US, αCD is generaly recognized as safe (GRAS) for oral use; in the EU, αCDs are approved for oral and parenteral use. 505(b)(2) is applicable. 問合せ
20/03/02 GEM159 Restoration of autophagy and reduction of inflammation Breast cancer and other carcinomas* Oral, intra-venous Oligo-saccharides Phase 2b/3 ready A novel intestinally absolrbable derivative (pat. pend.) of hydroxypropyl-α-cyclodextrin (HPαCD) that down-regulates the Phosphoinositide-system by controlling serum phospholipids and, thereby, reduces endocytosis. βCDs were effective in vivo against breast, ovarian, lung, and colon cancer, and metastatic melanoma, but need to be infused overnight and can cause permanent hearing loss. αCDs are not ototoxic and were more effective in vivo against growth and metastases of breast cancer.
*Mono- or adjuvant treatment. 505(b)(2) is applicable. 		問合せ
20/02/27 GEM158 Anti-mitotic chemotherapy Small cell lung cancer i.v. Small molecule Phase 1 completed Proprietary innovative albumin-stabilized pegylated liposomal docetaxel formulation. Elevated exposures of docetaxel compared with free (nonencapsulated) docetaxel were confirmed in animals and humans. Acceptable tolerability and results suggesting anti-tumor efficacy were observed in Phase 1. FDA orphan drug designation was granted and confirmed with FDA that 505(b)(2) NDA pathway appears to be an acceptable approach. 問合せ
20/02/21 GEM157 Combined adoptive cell therapy (autologous) Hepatocellular carcinoma （HCC）* Infusion Cell therapy Launch A combined adoptive cell therapy comprising cytokine-induced killer cells and activated cytotoxic T lymphocytes. In Phase III using patients whose tumors have been removed after curative resection for HCC, RFS was 44 months for the immunotherapy group while that of the control group was 30 months. The HR for tumor recurrence or death in the immunotherapy group vs the control group was 0.63. The mortality rate was reduced by 79% in the immunotherapy group vs the control group. Clinical trials for other solid tumors are ongoing.
*: Adjuvant therapy for patients whose tumors have been removed after curative resection for HCC. 		問合せ
20/02/18 GEM156 Chromatin destabilizing Solid and hematological tumors Oral, i.v., i.a Small molecule Phase 1 A First-In-Class chromatin destabilizing agent that intercalates into DNA, and interferes with histone/DNA binding changing its spatial structure. Consequent functional inactivation of a histone chaperon FACT leads to inhibition of several previously undruggable pro-cancer transcriptional factors, activation of p53 and interferon response. Dose-dependent nonclinical antitumor activity is seen in multiple models of solid and hematological tumors. Oral and i.v. phase 1 studies demonstrated a manageable safety profile and disease control with tumor regressions and protracted stable disease. 問合せ
20/02/18 GEM155 FPR2-specific ligand Atopic dermatitis/ Psoriasis, Dry eye disease, IBD （Inflammatory bowel disease）, Asthma, Rheumatoid arthritis Topical, Eye drop, s.c. Peptide Preclinical GEM155 is a small (7mer) lipidated peptide ligand for pro-resolving receptor FPR2 (N-formyl peptide receptor 2) involved in regulation of innate immune system and inhibition of ILC2 function (adaptive immune system). It also has anti-microbial effect for pathogenic bacteria through fusion with functional moiety. Efficacy is seen in animal models for the indications. CMC study is almost done. Toxicity study for topical usage and subcutaneous injection is going-on. Formulation for topical use is almost finished. 問合せ
20/02/18 GEM154 Collagen-inducing peptide Dermal filler, Cosmetics Topical Peptide Preclinical Laminin-derived peptide. Boosts collagen synthesis at sub-nanomolar concentration (Wrinkle-care) & inhibits melanin synthesis (Whitening). Registered cosmetic ingredient. 問合せ
20/02/18 GEM153 Angiogenic peptide Wound-care, Diabetic foot ulcer, Cosmetics Topical Peptide Preclinical Increases blood vessel formation (VEGFA/VEGFR1 expression ↑& cell proliferation/migration ↑). Boosts collagen synthesis at sub-nanomolar concentration (Wrinkle-care) & inhibits melanin synthesis (Whitening). Registered cosmetic ingredient. 問合せ
20/02/18 GEM152 Fat-adsorption inhibitor Obesity, Diabetes, Fatty liver Oral Natural product Preclinical Mushroom-derived natural product.
Reduces weight gain and obesity, blood glucose and lipid contents in the liver via reduction of lipid absorption in the gut. 		問合せ